These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8555084)

  • 1. Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran).
    Ramakrishna R; Manoharan A; Kwan YL; Kyle PW
    Br J Haematol; 1995 Nov; 91(3):736-8. PubMed ID: 8555084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?
    Kikta MJ; Keller MP; Humphrey PW; Silver D
    Surgery; 1993 Oct; 114(4):705-10. PubMed ID: 7692613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
    Wilde MI; Markham A
    Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.
    Polkinghorne KR; McMahon LP; Becker GJ
    Am J Kidney Dis; 2002 Nov; 40(5):990-5. PubMed ID: 12407644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery.
    Koster A; Meyer O; Hausmann H; Kuppe H; Hetzer R; Mertzlufft F
    J Clin Anesth; 2000 Jun; 12(4):324-7. PubMed ID: 10960207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thromboembolic complications in a patient with heparin-induced thrombocytopenia (HIT) showing cross-reactivity to a low molecular weight heparin-treatment with Org 10172 (Lomoparan).
    Muhm M; Claeys L; Huk I; Koppensteiner R; Kyrle PA; Minar E; Stümpflen A; Ehringer H; Polterauer P
    Wien Klin Wochenschr; 1997 Feb; 109(4):128-31. PubMed ID: 9076930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative review of the adverse effect profiles of heparins and heparinoids.
    Borris LC; Lassen MR
    Drug Saf; 1995 Jan; 12(1):26-31. PubMed ID: 7537967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium.
    Grocott HP; Root J; Berkowitz SD; deBruijn N; Landolfo K
    J Cardiothorac Vasc Anesth; 1997 Dec; 11(7):875-7. PubMed ID: 9412888
    [No Abstract]   [Full Text] [Related]  

  • 9. Eczematous plaques related to unfractionated and low-molecular-weight heparins: cross-reaction with danaparoid but not with desirudin.
    Martin L; Machet L; Gironet N; Pouplard C; Gruel Y; Vaillant L
    Contact Dermatitis; 2000 May; 42(5):295-6. PubMed ID: 10789857
    [No Abstract]   [Full Text] [Related]  

  • 10. Eczematous plaques related to unfractionated and low-molecular-weight heparin in pregnancy: cross-reaction with danaparoid sodium.
    Blickstein D; Hod M; Bar J
    Blood Coagul Fibrinolysis; 2003 Dec; 14(8):765-8. PubMed ID: 14614358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
    Kodityal S; Manhas AH; Udden M; Rice L
    Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed-type skin reaction to the heparin-alternative danaparoid.
    Szolar-Platzer C; Aberer W; Kränke B
    J Am Acad Dermatol; 2000 Nov; 43(5 Pt 2):920-2. PubMed ID: 11044823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Delayed hypersensitivity to heparins and heparinoids].
    Nicolie B; Bonneau JC; Le Sellin J; Gay G; Leclere JM; Drouet M
    Allerg Immunol (Paris); 2002 Feb; 34(2):47-50. PubMed ID: 11933754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thrombopenia increased by heparin and danaparoid].
    Godet G; Bertrand M; Van de Steen E; Boccara G; Koskas F
    Ann Fr Anesth Reanim; 2001 Jan; 20(1):50-3. PubMed ID: 11234580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172).
    Magnani HN
    Thromb Haemost; 1993 Oct; 70(4):554-61. PubMed ID: 7509508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia.
    Vun CM; Evans S; Chong BH
    Thromb Res; 1996 Mar; 81(5):525-32. PubMed ID: 8907311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia: role of adjunctive plasmapheresis.
    Schmahl KS; Ganjoo AK; Harloff MG
    J Cardiothorac Vasc Anesth; 1997 Apr; 11(2):262-3. PubMed ID: 9106004
    [No Abstract]   [Full Text] [Related]  

  • 18. Thrombosis during the use of the heparinoid Organon 10172 in a patient with heparin-induced thrombocytopenia.
    Insler SR; Kraenzler EJ; Bartholomew JR; Kottke-Marchant K; Lytle B; Starr NJ
    Anesthesiology; 1997 Feb; 86(2):495-8. PubMed ID: 9054269
    [No Abstract]   [Full Text] [Related]  

  • 19. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia.
    Gillis S; Merin G; Zahger D; Deeb M; Drenger B; Hyam E; Eldor A
    Br J Haematol; 1997 Sep; 98(3):657-9. PubMed ID: 9332322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
    Magnani HN; Gallus A
    Thromb Haemost; 2006 Jun; 95(6):967-81. PubMed ID: 16732376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.